Drug news
FDA approves generic Lovaza to reduce triglyceride (TG) levels- Teva
Teva Pharmaceutical Industries Ltd. has announced the approval on 8 April 2014 of the generic equivalent to Lovaza (Omega-3-Acid Ethyl Esters Capsules, USP), in the United States. Teva believes it is first-to-file and thus far is the only company to receive an approval from FDA. Teva plans to commence shipping immediately.
Lovaza Capsules, marketed by GlaxoSmithKline, had annual sales of approximately $1.1 billion in the United States, according to IMS data as of December 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins